XERIS PHARMACEUTICALS, INC.

Company Information

Company Name
XERIS PHARMACEUTICALS, INC.
Address
3208 Red River Street
Suite 300
Austin, TX, 78705-2659
Phone
n/a
URL
n/a
DUNS
609377135
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,179,571.00
3
SBIR Phase II
$2,159,612.00
3
Chart code to be here

Award List

  1. IMPROVED HYPOGLYCEMIA RESCUE DEVICE

    Amount: $157,478.00

    DESCRIPTION (provided by applicant): The objective of this program is to develop of a clinical prototype, semi-solid drug formulation and auto-injector pen that deliver microliter volumes of a glucago ...

    SBIR Phase I 2009 Department of Health and Human Services
  2. Improved Hypoglycemia Rescue Device

    Amount: $994,123.00

    DESCRIPTION (provided by applicant): The objective of this project is to demonstrate the safety, pharmacokinetics and initial efficacy of a ready-to-use Glucagon Rescue Pen that will deliver a very lo ...

    SBIR Phase II 2011 Department of Health and Human Services
  3. Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

    Amount: $343,124.00

    DESCRIPTION (provided by applicant): The objective of this program is to further the development of a novel, stable, non-aqueous glucagon formulation as an integral component of a bi-hormonal (insulin ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Development of an Electromyographically Controlled Electrolarynx Voice Prosthesis

    Amount: $678,969.00

    DESCRIPTION (provided by applicant): The program outlined in this application has been designed to accelerate the development and commercialization of a Glucagon Mini-Dose Pen to change the paradigm f ...

    SBIR Phase I 2013 Department of Health and Human Services
  5. Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

    Amount: $713,733.00

    DESCRIPTION (provided by applicant): The objective of this program is to further the development of a novel, stable, non-aqueous glucagon formulation as an integral component of a bi-hormonal (insulin ...

    SBIR Phase II 2013 Department of Health and Human Services
  6. Glucagon Mini-Dosing Pen for Treatment of Hypoglycemia

    Amount: $451,756.00

    DESCRIPTION (provided by applicant): The program outlined in this application has been designed to accelerate the development and commercialization of a Glucagon Mini-Dose Pen to change the paradigm f ...

    SBIR Phase II 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government